428
Vol. 58, No. 3
3.42 (1H, m), 3.61—3.69 (3H, m), 4.08—4.16 (2H, m), 7.24—7.34 (6H, m),
7.48—7.52 (4H, m); 13C-NMR (126 MHz, CDCl3) d: 25.5, 25.7, 29.4, 29.5
(2ꢂC), 33.1, 33.4, 66.8, 70.0, 72.3, 76.8, 109.3, 126.2, 127.8, 127.9, 128.1,
142.8; HR-MS (EI) Calcd for C25H34O4 (Mꢃ) 398.2452, Found 398.2457.
25.4, 25.9, 28.6, 29.2, 29.4 (3ꢂC), 29.5, 33.1, 65.1, 66.8, 72.3, 128.3, 129.5,
130.5, 132.8, 166.7; HR-MS (FAB) Calcd for C18H29O4 (MꢃꢃH) 309.2066,
Found 309.2050.
11-tert-Butyldimethylsilyloxy-undecane-1,2-diol (2e) (Table 2, Entry
5) According to the general procedure, the treatment of 1e (66.4 mg,
0.201 mmol) with 2,2ꢀ-bipyridyl (94.8 mg, 0.607 mmol) and TMSOTf
(73.1 ml, 0.404 mmol), then treatment of Et2O (2 ml) and saturated NH4Cl
aq. (2 ml) for 6.5 h gave 2e (46.2 mg, 72%). Eluent; hexanes/AcOEt (1/1) to
AcOEt. White solid. 1H-NMR (500 MHz, CDCl3) d: 0.00 (6H, s), 0.85 (9H,
s), 1.23—1.46 (16H, m), 2.41 (2H, s), 3.36—3.40 (1H, m), 3.53—3.65 (4H,
m); 13C-NMR (126 MHz, CDCl3) d: ꢄ5.3, 18.4, 25.5, 25.8, 26.0, 29.4, 29.5
(2ꢂC), 29.6, 32.8, 33.1, 63.3, 66.8, 72.3; HR-MS (FAB) Calcd for
C17H39O3Si (MꢃꢃH) 319.2668, Found 319.2669.
11-Triphenylmethyloxy-undecane-1,2-diol (2f) (Table 2, Entry 6)
According to the general procedure, the treatment of 1f (92.5 mg,
0.202 mmol) with 2,2ꢀ-bipyridyl (94.8 mg, 0.607 mmol) and TMSOTf
(73.1 ml, 0.404 mmol), then treatment of Et2O (2 ml) and 1 N HCl (2 ml) for
4.5 h gave 2f (77.5 mg, 86%). Eluent; hexanes/AcOEt (1/1). White solid. 1H-
NMR (500 MHz, CDCl3) d: 1.26—1.42 (16H, m), 1.58—1.66 (2H, m), 2.04
(1H, br s), 2.14 (1H, br s), 3.03 (2H, t, Jꢁ6.7 Hz), 3.40—3.44 (1H, m),
3.63—3.70 (2H, m), 7.20—7.45 (15H, m); 13C-NMR (126 MHz, CDCl3) d:
25.5, 26.4, 29.5, 29.6, 30.0, 33.2, 63.7, 66.8, 72.3, 86.2, 126.8, 127.7, 128.7,
144.5; HR-MS (FAB) Calcd for C30H38O3Na (MꢃꢃNa) 469.2719, Found
469.2724.
Acknowledgment This work was supported by a Grant-in-Aid for Sci-
entific Research (B) and for Scientific Research for Exploratory Research
from Japan Society for the Promotion of Science (JSPS) and Special Coordi-
nation Funds for Promoting Science and Technology of the Ministry of Edu-
cation, Culture, Science and Technology, the Japanese Government.
References and Notes
1) Wuts P. G. W., Greene T. W., “Greene’s Protective Groups in Organic
Synthesis,” 4th ed., John Wiley & Sons, Inc., New Jersey, 2006.
2) Kocien´ski P. J., “Protecting Groups,” 3rd ed., Georg Thieme Verlag,
Stuttgart, 2005.
3) Ness A. T., Hann R. M., Hudson C. S., J. Am. Chem. Soc., 66, 665—
670 (1944).
4) Hann R. M., Ness A. T., Hudson C. S., J. Am. Chem. Soc., 66, 670—
673 (1944).
5) Hough L., Jones J. K. N., Magson M. S., J. Chem. Soc., 1952, 1525—
1527 (1952).
6) Bonner T. G., Methods Carbohydr. Chem. II, 1963, 314—317 (1963).
7) Schlessinger R. H., Wood J. L., J. Org. Chem., 51, 2621—2623 (1986).
8) McCombie S. W., Metz W. A., Tetrahedron Lett., 28, 383—386
(1987).
9) Wanner M. J., Willard N. P., Koomen G.-J., Pandit U. K., Tetrahedron,
43, 2549—2556 (1987).
10) Niwa H., Okamoto O., Yamada K., Tetrahedron Lett., 29, 5139—5142
(1988).
11) Gras J.-L., Pellissier H., Nouguier R., J. Org. Chem., 54, 5675—5677
(1989).
1-Hydroxymethylcyclohexanol (2g) (Table 2, Entry 7)23) According to
the general procedure, the treatment of 1g (21.3 mg, 0.150 mmol) with 2,2ꢀ-
bipyridyl (140.6 mg, 0.900 mmol) and TMSOTf (110 ml, 0.609 mmol), then
treatment of Et2O (2 ml) and 1 N HCl (2 ml) for 1 h gave 2g (18.5 mg, 95%).
Eluent; hexanes/AcOEt (2/1) to hexanes/AcOEt (1/1).
(ꢁ)-trans-Octane-4,5-diol (2h) (Table 2, Entry 8)24) According to the
general procedure, the treatment of 1h (31.3 mg, 0.198 mmol) with 2,2ꢀ-
bipyridyl (185 mg, 1.19 mmol) and TMSOTf (143 ml, 0.791 mmol), then
treatment of Et2O (2 ml) and 1 N HCl (2 ml) for 1.5 h gave 2h (16.1 mg,
56%). Eluent; hexanes/AcOEt (3/1).
12) Nazarov M. N., Kulak L. G., Zlotskii S. S., Rakhmankulov D. L.,
Paushkin Y. M., Dokl. Akad. Nauk, 308, 1388—1389 (1989).
13) Shibasaki H., Furuta T., Kasuya Y., Steroids, 57, 13—17 (1992).
14) Elmorsy S. S., Bhatt M. V., Pelter A., Tetrahedron Lett., 33, 1657—
1660 (1992).
cis-1,2-Cyclohexanediol (2i) (Table 2, Entry 9)20) According to the
general procedure, the treatment of 1i (25.4 mg, 0.198 mmol) with 2,2ꢀ-
bipyridyl (92.9 mg, 0.595 mmol) and TMSOTf (72 ml, 0.396 mmol), then
treatment of Et2O (2 ml) and 1 N HCl (2 ml) for 0.5 h gave 2i (19.7 mg, 86%).
Eluent; hexanes/AcOEt (1/1) to AcOEt.
15) Kawabata T., Kiryu Y., Sugiura Y., Fuji K., Tetrahedron Lett., 34,
5127—5130 (1993).
3-Phenylpropane-1,3-diol (2j) (Table 2, Entry 10)25) According to the
general procedure, the treatment of 1j (33.3 mg, 0.203 mmol) with 2,2ꢀ-
bipyridyl (200 mg, 1.28 mmol) and TMSOTf (146 ml, 0.808 mmol), then
treatment of Et2O (2 ml) and 1 N HCl (2 ml) for 1.5 h gave 2j (27.9 mg,
84%). Eluent; hexanes/AcOEt (1/1).
The Selective Deprotection of 4. 4-{9ꢀ,10ꢀ-Dihydroxydecyl}-2,2-
diphenyl-1,3-dioxolane (5) (Chart 3) TMSOTf (73.1 ml, 0.404 mmol)
was added to a solution of methylene acetal 4 (82.9 mg, 0.202 mmol) and
2,2ꢀ-bipyridyl (94.6 mg, 0.606 mmol) in CH2Cl2 (0.4 ml) at 0 °C under N2.
The reaction mixture was stirred for 30 min at 0 °C. After disappearance of 4
on TLC, Et2O (2 ml) and 1 N HCl (2 ml) was added to the reaction mixture.
The resulting solution was stirred until disappearance of the pyridinium salt
(highly polar compound). The mixture was extracted with CH2Cl2. The com-
bined organic layer was dried over Na2SO4, filtered, and evaporated in
vacuo. The residue was purified by flash SiO2 column chromatography
(hexanes/AcOEtꢁ1/1) to give a diol 5 (63.1 mg, 78%). White solid; 1H-
NMR (500 MHz, CDCl3) d: 1.24—1.74 (16H, m), 2.38 (2H, br s), 3.39—
16) Fujioka H., Okitsu T., Ohnaka T., Sawama Y., Kubo O., Okamoto K.,
Kita Y., Adv. Synth. Catal., 349, 636—646 (2007).
17) Fujioka H., Kubo O., Okamoto K., Senami K., Okitsu T., Ohnaka T.,
Sawama Y., Kita Y., Heterocycles, 77, 1089—1103 (2009).
18) Fujioka H., Kubo O., Senami K., Minamitsuji Y., Maegawa T., Chem.
Commun., 2009, 4429—4431 (2009).
19) Fujioka H., Senami K., Kubo O., Yahata K., Minamitsuji Y., Maegawa
T., Org. Lett., 11, 5138—5141 (2009).
20) Commercially available.
21) Park J., Pedersen S. F., Tetrahedron, 48, 2069—2080 (1992).
22) Anelli P. L., Czech B., Montanari F., Quici S., J. Am. Chem. Soc., 106,
861—869 (1984).
23) Ortiz J., Guijarro A., Yus M., Eur. J. Org. Chem., 1999, 3005—3012
(1999).
24) Kaburagi Y., Kishi Y., Org. Lett., 9, 723—726 (2007).
25) Jernigan M. T., Eliel E. L., J. Am. Chem. Soc., 117, 9638—9644
(1995).